AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04255290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leg Squat Lounge
Description: The players assigned to the experimental group will receive an intervention through plyometric and eccentric hamstring exercises
Study NCT04255290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The subjects included in the control group will perform an eccentric work protocol
Study NCT03016221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axanova hot gel
Description: Axanova hot gel is a topical product with a warming effect. It contains menthol, pine needle oil, wintergreen oil, rosemary oil, eucalyptus oil, incense oil.
Study NCT03016221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Axanova activ gel
Description: Axanova activ gel is a topical product with a revulsive effect. It contains menthol, pine needle oil, orange oil, lemon oil, wintergreen oil, glycosaminoglycans.
Study NCT03016221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perskindol Dolo Gel
Description: Perskindol Dolo Gel is a topical product with a warming effect. It contains wintergreen oil, pine needle oil, aromatics, excipients.
Study NCT03016221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perskindol Classic Gel
Description: Perskindol Classic Gel is a topical product with a revulsive effect. It contains menthol, wintergreen oil, pine needle oil, lemon oil, orange peel oil, lemon bergamot oil, rosemary oil, lavender oil, excipients.
Study NCT03016221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perskindol Cool Kühl-Gel
Description: Perskindol Cool Kühl-Gel is a topical product with a cooling effect. It contains levomenthol, color E131, aromatics, excipients.
Study NCT03016221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dolor-X Hot Gel
Description: Dolor-X Hot Gel is a topical product with a warming effect. It contains isopropyl alcohol, water, menthol, hyprolose, camphor, trometamol, paprika, wintergreen oil, excipients.
Study NCT01037985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXC 001
Description: Multiple intradermal injections of EXC 001 and placebo
Study NCT03016221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dolor-X Classic Gel
Description: Dolor-X Classic Gel is a revulsive product. It contains water, isopropyl alcohol, menthol, spruce, hyprolose, trometamol, wintergreen oil, excipients.
Study NCT03016221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dolor-X Cool Gel
Description: Dolor-X Cool Gel is a cooling product. It contains water, isopropyl alcohol, menthol, trometamol, color E131, excipients.
Study NCT03898895 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy+anti-PD-1 antibody
Description: The total radiation dose is over 45Gy without damaging organic fucntion. Conventional intensity-modulated radiotherapy or stereotactic body radiation therapy are both allowed. Camrelizumab 200mg intravenously every 3 weeks will be initiated within 7 days after radiotherapy. Patients will receive camrelizumab until clinical or radiographic disease progression, unacceptable toxicity, death or withdrawal. If disease progression is confirmed by radiologic examinations, another 200mg camrelizumab should be applied to the patient, then another radiologic examination will be performed 4 weeks later to confirm or exclude progression. If progression is confirmed, the camrelizumab should be stopped.
Study NCT02273336 — intervention group
Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Undergo tissue and blood sample collection
Study NCT03623334 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Radiation Therapy
Description: Radiotherapy to a potent tumorcidal dose
Study NCT02273336 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02701166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: bezafibrate 400mg per day
Study NCT02701166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 400mg per day
Study NCT03235661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
Study NCT03235661 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nCPAP
Description: nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
Study NCT00172536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
Study NCT00172536 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
Study NCT01703936 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agricultural and life skills training program
Study NCT01037985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple intradermal injections of EXC 001 and placebo
Study NCT04487002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection
Study NCT00817076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desloratadine
Description: desloratadine syrup; 5.0 mL once daily for 28 days
Study NCT00085774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol aerosol by HFA MDI
Description: albuterol HFA MDI 160 mcg
Study NCT00085774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol aerosol by HFA BOI
Description: albuterol HFA BOI 160 mcg
Study NCT00085774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo aerosol by HFA
Description: placebo HFA
Study NCT03858595 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self monitoring of blood pressure using Health Gauge Device and monthly monitoring of weight gain
Description: Women in the intervention arm will be provided with the Health Gauge device. With this device, the women will be able to do self-monitoring of blood pressure as well as a few other things like heart rate, daily activities. We will also measure weight gain of the mothers at monthly basis.
Study NCT01201941 — intervention group
Intervention type: OTHER
Intervention: e-Chasqui
Description: The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests.
Study NCT04002336 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Voice therapy
Description: Traditional method of voice therapy
Study NCT01030107 — intervention group
Intervention type: BEHAVIORAL
Intervention: Increase Sleep
Description: Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
Study NCT04002336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice Therapy App
Description: Smartphone app, which allows participants to record home practice sessions in real time and upload sessions to the app server for the clinician to access and track.
Study NCT00577278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative Studies
Study NCT03965403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm motor function retraining with BURT
Description: Intervention will be focused on patients impairments to assess the feasibility of the BURT device to carry-on long interventions
Study NCT01030107 — intervention group
Intervention type: BEHAVIORAL
Intervention: Decrease Sleep
Description: Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
Study NCT03664960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK002
Description: AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Study NCT03116620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chewing evaluation
Description: Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
Study NCT02811263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Equal volume of normal saline to be used as placebo
Study NCT02811263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin
Description: Epogen drawn from commercially available single dose 4000U/mL vials
Study NCT04177563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body cryostimulation
Description: Whole-body cryotherapy
Study NCT04632537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine
Description: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine will be diluted in preservative-free saline and given intradermally (0.1mL) in the deltoid area.
Study NCT04632537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative-free saline
Description: Placebo will be administered in an intradermal route in the same location as the BCG vaccines: upper arm. Placebo will comprise 0.1 mL of the diluent (preservative-free saline) to ensure the same quantity and same color as the resuspended BCG vaccine, rendering the two indistinguishable.
Study NCT02886195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500mg/m2 ivgtt d1, per three weeks
Study NCT02886195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500mg/m2 ivgtt d1, per three weeks
Study NCT02886195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: 80mg/m2 ivgtt d1, per three weeks
Study NCT02886195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80mg/m2 ivgtt d1, per three weeks
Study NCT02886195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150mg po. every day
Study NCT02886195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150mg po. every day
Study NCT03508661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIN-SSLED Program
Description: The program includes 13 modules that will be delivered live via webinar over the course of the 3-month program. Each module will be delivered in a 60- to 90-minute session. Module topics include (1) the leader's role; (2) starting a support group; (3) structuring a support group meeting; (4) scleroderma 101; (5) successful support group culture; (6 \&7) managing support group dynamics I and II; (8) grief and crisis in scleroderma; (9) marketing and recruitment; (10) the continuity of the group; (11) supporting yourself as a leader; (12) virtual support group meetings, (13) support group leader resources. Participants will receive a workbook, be shown filmed vignettes, and will have access to an online resource center.
Study NCT00709033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous or syngeneic PBTLs and EBV-CTLs
Description: Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2
Study NCT03569306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENB
Description: ENB is carried out by a ENB system（LungCare, China) which can offer real-time navigation for bronchoscopy reaching peripheral pulmonary nodules.
Study NCT03569306 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
Study NCT03569306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBUS-GS
Description: EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
Study NCT02585999 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Xulane Contraceptive Patch
Description: Extended use (12 weeks) of contraceptive patch
Study NCT01593579 — intervention group
Intervention type: BEHAVIORAL
Intervention: Autonomic Function Tests
Description: Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine \& standing heart rate \& blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
Study NCT01593579 — intervention group
Intervention type: OTHER
Intervention: supine and standing catecholamines
Description: patients will have blood drawn from supine and standing catecholamines.
Study NCT03582735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve gliding exercise
Description: A 4-week home-based nerve-gliding exercise program (NGEP) including isolated and coupled upper limb and neck movements. A specific mobilization was elaborated for each week of the program allowing to gradually increase the range of movement and inter-articular coordination.
Study NCT00363051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg
Description: Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
Study NCT00363051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Depot
Study NCT02212002 — intervention group
Intervention type: DRUG
Intervention: IAP
Description: maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
Study NCT02581163 — intervention group
Intervention type: DRUG
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Co-formulated tablet
Study NCT02581163 — intervention group
Intervention type: DRUG
Intervention: Dasabuvir
Description: Tablet
Study NCT02581163 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Tablet
Study NCT01809665 — intervention group
Intervention type: DEVICE
Intervention: ICD/CRT-P therapy
Study NCT01809665 — intervention group
Intervention type: OTHER
Intervention: MRI
Study NCT01926743 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy
Description: 0.75mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
Study NCT02292537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered by intrathecal (IT) lumbar puncture (LP) injection
Study NCT02292537 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Small needle prick on the lower back at the location where the IT injection is normally made
Study NCT00997490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)
Description: 3 x 2 tablets/day over 6 weeks
Study NCT00997490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: film-coated sugar-pill
Description: 3 x 2 tablets / day over 6 weeks
Study NCT03776500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169
Description: PBTZ169 crystalline supplied as powder for oral solution
Study NCT03776500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo supplied as powder for oral solution
Study NCT00003645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: 10.8 mg intramuscularly once every 3 months for 12 months
Study NCT00003645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: 50 mg tablet orally daily for 12 months
Study NCT03280368 — intervention group
Intervention type: OTHER
Intervention: Bloodtest
Study NCT03280368 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Study NCT00205699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: randomized to begin 12 week trial of risperidone
Study NCT00205699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: randomized to begin 12 week trial of olanzapine
Study NCT00205699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole
Description: randomized to 12 week trial of aripiprazole
Study NCT03053726 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Variable Frequency Stimulation
Description: vary the frequency of the stimulation parameter
Study NCT04099979 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study
Study NCT03053726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Variable Frequency Stimulation
Description: vary the frequency of the stimulation parameter
Study NCT04230798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury prevention program
Description: The intervention program consisted in 16 sessions, performed during eight weeks, twice per week. Intervention group performed 20 minutes sessions before their habitual volleyball training. The structure of the prevention program consisted in a warm up, a lower limb strength exercise; two core exercises; a lower limb plyometric exercise, and a lower limb stability exercise. While the injury prevention program was being performed, both groups continued with their volleyball training sessions.
Study NCT03955471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.
Study NCT02334670 — intervention group
Intervention type: DRUG
Intervention: Fluconazole
Description: HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
Study NCT03955471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).
Study NCT01310673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol 300mg po QD for 30 days.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days.
Study NCT01310673 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.~Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days.
Study NCT01359644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSI-7977
Description: Tablets, oral, 400 mg, once daily
Study NCT01581788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium ER Tablets, 500 mg